Increased aggressiveness of thyroid cancer in patients with graves’ disease

Journal of Clinical Endocrinology and Metabolism

Volumn 70, Issue 4, 1990, Pages 830-835

  Belfiore, Antonino ^a,b   Rita Garofalo, Maria ^a,b   Giuffrida, Dario ^a,b   Runello, Filippo ^a,b   Filetti, Sebastiano ^a,b,c   Fiumara, Antonino ^b   Ippolito, Orazio ^a   Vigneri, Riccardo ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

THYROID STIMULATING IMMUNOGLOBULIN;

ADULT; ARTICLE; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; THYROID CANCER; THYROID TOXIC ADENOMA;

GRAVES' DISEASE; HUMAN; SUPPORT, NON-U.S. GOV'T; THYROID NEOPLASMS;

EID: 0025266650     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-70-4-830     Document Type: Article

References (33)

1. Mazzaferri EL. Treatment of carcinoma of follicular epithelium. In: Ingbar SH, Bravermann LE, eds. The thyroid. A fundamental and clinical text, 5th ed. Philadelphia: Lippincot; 1986; 1329-48.
2. Clark OH, Caster BJ. Thyrotropin “receptors” in normal and neoplastic human thyroid tissue. Surgery. 1979;85:624-32.
3. Abe Y, Ichikawa Y, Muraki T, Ito K, Homma M. Thyrotropin (TSH) receptor and adenylate cyclase activity in human thyroid tumors: absence of high affinity receptor and loss of TSH responsiveness in undifferentiated thyroid carcinoma. J Clin Endocrinol Metab. 1981;52:23-28.
4. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg. 1981;5:39-47.
5. Filetti S, Belfiore A, Amir SM, et al. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med. 1988;318:753-9.
6. Burman KD, Baker Jr JR. Immune mechanisms in Graves’ disease. Endocr Rev. 1985;6:183-232.
7. Rapaport, B, Filetti S, Takai N, Seto P, Halverson G. Studies on the cyclic AMP response to thyroid stimulating immunoglobulin (TSI) and thyrotropin (TSH) in human thyroid cell monolayers. Metabolism 1982;31:1159-67.
8. 131I and surgical treatment. J Nucl Med 1967;8:515-28.
9. Belfiore A, Sava L, Runello F, Tomaselli L, Vigneri R. Solitary autonomously functioning thyroid nodules and iodine deficiency. J Clin Endocrinol Metab. 1983;56:283-7.
10. 131I uptake method. Bull NY Acad Med. 1955;31:137-41.
11. Studer H. Simple goiter and its variants: euthyroid and hyperthyroid uni- and multinodular goiter: In: Labhart A, ed. Clinical endocrinology: theory and practice, 2nd ed. Berlin: Springer-Velag; 1986;265-72.
12. Solomon DH. Treatment of Graves’ disease hyperthyroidism: In: Ingbar SH, Braverman LE, eds. The thyroid. A fundamental and clinical text, 5th ed. Philadelphia: Lippincot; 1986;987-1014.
13. Miller JM, Block MA. The autonomous functioning thyroid nodule: therapeutic considerations. Arch Surg. 1968;96:386-93.
14. Lowhagen T. Thyroid: In: Wied G, Zaijcek J, eds. Aspiration biopsy cytology. I. Cytology of supradiaphragmatic organs. Basel: Karger; 1974;67-89 (Monogr Clin Cytol, vol 4).
15. Hedinger CHR, Sobin LH. Histological typing of thyroid tumors. Geneva: World Health Organization, 1974;17-27 (International histological classification of tumors; vol 11).
16. Shapiro SJ, Friedman NB, Perzik SL, Catz B. Incidence of thyroid carcinoma in Graves’ disease. Cancer 1970;26:1261-70.
17. Farbota LM, Calandra DB, Lawrence AM, Paloyan R. Thyroid carcinoma in Graves’ disease. Surgery 1985;98:1148-52.
18. Pacini F, Elisei R, Di Coscio GC, et al. Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest. 1988;11:107-12.
19. Koning MP, Ruchi LH, Studer H, Berchtold R, Rosier H. Thyroid cancer in regions of edemic goiter: In: Andreoli M, Monaco F, Robbins J, eds. Advances in thyroid neoplasia. Rome: Field Educational Italie; 1981;177-87.
20. Belfiore A, La Rosa GL, Padova G, Sava L, Ippolito O, Vigneri R. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. Cancer 1987;60:3096-102.
21. Williams ED. Epidemiology and genetic factors in thyroid carcinoma. Acta Endocrinol (Copenh). 1983;252(Suppl):11.
22. Stoffer SS, Van Dyke DL, Vaden Bach J, Szpunar W, Weiss L. Familial papillary carcinoma of the thyroid. Am J Med Genet. 1986;25:775-82.
23. De Groot L., Paloyan E. Thyroid carcinoma and radiation: a Chicago endemic. JAMA 1973;225:487-91.
24. Schneider AB, Shore-Freedman E, Weinstein RA. Radiation induced thyroid and other head and neck tumors: occurrence of multiple tumors and analysis of risk factors. J Clin Endocrinol Metab. 1986;63:107-12.
25. DeGroot LJ, Larsen PR, Refetoff S, Stanbury JB. The thyroid and its diseases, 5th ed. New York: Wiley and Sons; 1984;756-831.
26. Cady B, Sedgwick CE, Meissner WA, Bookwalter JR, Romagosa V, Weber J. Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg. 1976;184:541-53.
27. Rees Smith B, Mc Lachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev. 1988;9:106-21.
28. Doniach I, Williams ED. The development of thyroid and pituitary tumours in the rat 2 years after partial thyroidectomy. Br J Cancer. 1962;16:222-31.
29. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of impact of therapy in 576 patients. Am J Med. 1981;70:511-8.
30. Ishikawa N, Eguchi K, Otsubo T et al. Reduction in the suppressor-inducer T cell-subset and increase in the helper T cell subset in thyroid tissue from patients with Graves’ disease. J Clin Endocrinol Metab. 1987;65:17-23.
31. Weetman AP, Mc Gregor AM. Autoimmune thyroid disease: developments in our understanding. Endocr Rev. 1984;5:309-55.
32. Lucas-Martin A, Foz-Sala M, Todd I, Bottazzo GF, Puiol-Borrell R. Occurrence of thyrocyte HLA class II expression in a wide variety of thyroid disease: relationship with lymphocytic infiltration and thyroid autoantibodies. J Clin Endocrinol Metab. 1988;66:367-75.
33. Hanafusa T, Pujol-Burrell R, Chiovato L, Russell RCG, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigen on thyrocytes in Graves’ disease: relevance for autoimmunity. Lancet. 1983;2:1111-5.